RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Prävention der Mutter-zu-Kind-Übertragung des Hepatitis-B-Virus
Leitlinie zur antiviralen Prophylaxe während der Schwangerschaft
Harlfinger, J., Nußbaumer-Streit, B., & Gartlehner, G. (2023). Prävention der Mutter-zu-Kind-Übertragung des Hepatitis-B-Virus: Leitlinie zur antiviralen Prophylaxe während der Schwangerschaft. Gesundheitswesen, 85(04), 266-269. https://doi.org/10.1055/a-1630-7893
BACKGROUND: Most HBV-associated deaths among adults are secondary to infections acquired at birth or in the first five years of life.
AIM: To extend the guideline for the prevention of mother-to-child transmission of the hepatitis B virus to include antiviral prophylaxis.
METHODS: The guideline was developed by the World Health Organization (WHO) in accordance with WHO standards. The summary was translated into German by employees of the WHO Collaborating Centre at Danube University Krems (Austria).
RESULTS: In addition to the recommendation to test pregnant women for heptatitis B virus (HBV) and vaccinate newborns against hepatitis B as soon as possible after birth, two new recommendations have been formulated: pregnant women testing positive for HBV infection should receive tenofovir prophylaxis to prevent mother-to-child transmission of HBV. WHO recommends that in settings in which antenatal HBV DNA testing is not available, HBeAg testing can be used as an alternative to determine eligibility for tenofovir prophylaxis.
